Participated · Series A · Aug 2026

Whif is an interactive content platform that enables users to form relationships with AI characters and generate evolving narratives through conversation, with anyone able to create and share characters. The service emphasizes relationship- and story-driven interactions rather than predetermined question-and-answer responses, positioning users as creators as well as consumers. Launched in mid-2025, Whif achieved rapid growth: paying users average 217 minutes of daily engagement, payment volume grew at an average monthly rate of 110% over nine months, and monthly revenue expanded 1,000-fold within a year. Whif operates in 13 countries and derives roughly 40% of revenue from overseas markets, targeting over 60% by year-end. The company plans to move the product into a multimodal phase—integrating images and video and extending characters into IP like webtoons, videos, and games—and is expanding headcount across development, planning, design, and marketing to support these plans.

Participated · Series A · Aug 2026

Founded in June 2021 by Oh Hyun-ung, Step Lab develops space-grade mechanism technology including a launch-vibration-reducing separation ring used to connect and detach satellites from launch vehicles. Its flagship products include the separation ring and STEP POD, a CubeSat deployer that integrates an in-house vibration isolation system and is slated to fly aboard DaejeonSAT-1, giving the company its first flight heritage. Step Lab has expanded into payload technology, building a 4-meter-class, three-stage deployable SAR mesh antenna and developing an AI-based zoom optical module for space domain awareness through Korea’s Scale-up TIPS program. The company has also developed full small-satellite systems-integration capability via its DaejeonSAT-1 work, which will carry a selfie camera to confirm on-orbit status. With the recent Series A, Step Lab plans to scale mass production of its flight-proven mechanisms and accelerate global commercialization.

Participated · Series C · Jul 2026

Founded in 2015, Nexusbe designs ALD equipment and proprietary gas-injector technology that enables nanometer-scale precise thin-film deposition. Its ALD systems are applied across semiconductors, displays, high-efficiency solar cells and secondary-battery electrode and separator coatings, and the company supplies equipment to more than 70 universities and research institutes. Nexusbe established a sales subsidiary in China last year and is expanding local commercial efforts in response to the Chinese solar-cell market. The company reported successive institutional financings since 2021 and has a cumulative funding total of 290억 won following the completed Series C. Management plans to accelerate ALD technology development and scale mass-production deployment, and is preparing for a KOSDAQ IPO with joint lead managers already appointed.

Participated · Equity · Jun 2026

THE SMC offers brand content and social media marketing services built around its proprietary analytics platform, Lens by The SMC. Lens leverages a database of over 100,000 creator profiles to help optimize brand campaigns and social media engagement. The company emphasizes AI-powered creator marketing across social channels. Founded by Yongtae Kim and based in South Korea, THE SMC recently raised $13 million in a pre-IPO round to fund AI development, overseas expansion, and hiring. The financing positions the company to scale its analytics and creator-matching capabilities as it pursues broader market growth.

Participated · Series B · Jun 2026

Promedius develops Osteo Signal, an AI-based screening solution that analyzes routine chest radiographs to assess osteoporosis risk in about three seconds and identify at-risk patient groups without additional tests. Osteo Signal was designated an innovative medical device in 2024 and received approval from the Korean Ministry of Food and Drug Safety in 2025; the company has also secured regulatory approvals in Vietnam and Indonesia and is seeking FDA and CE/MDR clearances by the end of the year. Promedius has built partnerships with global medical device companies such as Siemens Healthineers and secured strategic investors including Daewoong Pharmaceutical and Naver to support commercial rollout. The company aims to commercialize nationally and expand internationally while broadening its platform to address healthy aging conditions like sarcopenia, metabolic and cardiovascular diseases. Its total funding now exceeds 35 billion won following the recent Series B raise of 21.5 billion won.